2024년에 12억 달러로 추정되는 세계의 제약용 AI 시장은 분석 기간인 2024-2030년에 CAGR 30.1%로 성장하며, 2030년에는 58억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 AI 하드웨어는 CAGR 31.6%를 기록하며, 분석 기간 종료시에는 36억 달러에 달할 것으로 예측됩니다. AI 소프트웨어 분야의 성장률은 분석 기간에 CAGR 27.0%로 추정됩니다.
미국 시장은 3억 1,450만 달러로 추정, 중국은 CAGR 28.5%로 성장 예측
미국의 제약용 AI 시장은 2024년에 3억 1,450만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 분석 기간인 2024-2030년의 CAGR을 28.5%로 2030년까지 8억 7,370만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 27.7%와 25.9%로 예측됩니다. 유럽에서는 독일이 CAGR 20.8%로 성장할 것으로 예측됩니다.
세계 제약업계의 AI 시장 - 주요 동향 및 촉진요인 정리
AI가 제약업계의 게임 체인저가 되고 있는 이유는 무엇인가?
인공지능(AI)은 의약품의 발견, 개발, 제조 및 시장 출시 방식을 재구성함으로써 제약 산업을 빠르게 변화시키고 있습니다. 의약품 개발 비용, 시간, 데이터 양이 증가함에 따라 AI는 R&D 워크플로우를 간소화하고, 신약 후보물질을 식별하며, 임상시험 설계를 최적화할 수 있는 강력한 툴을 제공합니다. 전통적인 제약 모델은 하나의 의약품을 출시하는 데 10년 이상, 수십억 달러가 소요되고 개발 중단률이 높은 경우가 많으며, AI, 특히 머신러닝(ML)과 딥러닝은 히트 투 리드(hit-to-lead) 식별, 화합물의 효능 및 독성 예측, 기존 약물의 재사용을 보다 정확하고 신속하게 수행할 수 있도록 도와줍니다. 이러한 비효율성을 해결하고 있습니다.
오믹스 데이터와 전자의무기록부터 생물의학 문헌과 분자 라이브러리까지 방대한 데이터세트를 분석하는 AI의 능력은 보다 타겟팅된 가설 중심의 신약개발 접근을 가능하게 합니다. 제약사들은 AI를 활용하여 질병 메커니즘과 치료 경로의 숨겨진 관계를 밝혀내고, 초기 단계의 연구개발에서 시행착오의 요소를 크게 줄이고 있습니다. 또한 AI는 의사 대상 개인화, 가격 전략 최적화, 수요 예측, 환자 순응도 향상 등 상업적 활동에도 도입되고 있습니다. 제약사들이 데이터 중심의 혁신 모델로 전환하는 가운데, AI는 경쟁 우위와 업무 민첩성의 중심이 되고 있습니다.
AI 기반 플랫폼은 어떻게 신약개발과 임상개발을 가속화할 수 있는가?
AI는 예측 모델링, 분자 시뮬레이션, 자동화된 하이스루풋 스크리닝을 통해 신약개발의 타임라인을 크게 단축하고 있습니다. 방대한 화합물 데이터세트으로 훈련된 딥러닝 알고리즘은 생물학적 활성, 결합 친화도, ADMET(흡수, 분포, 대사, 배설, 독성) 특성, 오프타겟 효과를 예측할 수 있으며, 연구자들은 가장 유망한 후보 화합물에 집중할 수 있습니다. 또한 자연 언어 처리(NLP) 툴은 과학 문헌과 임상시험 데이터베이스에서 실용적인 지식을 추출하여 표적 검증과 가설 생성을 강화합니다.
임상 개발에서 AI는 임상시험의 설계와 수행을 변화시키고 있습니다. 머신러닝 모델은 최적의 임상시험 실시기관을 선정하고, 환자 모집률을 예측하며, 유전적 또는 표현형 데이터를 기반으로 치료에 가장 잘 반응할 가능성이 높은 집단을 선별하는 데 사용되고 있으며, AI를 활용한 원격 모니터링과 실제 데이터 통합은 적응형 임상시험 설계와 시판 후 감시를 강화하고, 안전성 및 규제 평가 안전성 평가와 규제 준수를 개선하고 있습니다. 이러한 효율성은 비용 절감과 감소뿐만 아니라 개인화된 의료 패러다임에 부합하는 정밀한 시험의 길을 열어주며, AI가 신약 개발과 전달의 간극을 계속 메우면서 의약품 개발 수명주기을 보다 신속하고 예측 가능하며 환자 중심의 프로세스로 재구성하고 있습니다. 재구성되고 있습니다.
제약업계의 AI 도입이 가속화되고 있는 곳은 어디이며, 어떤 이해관계자가 주도하고 있는가?
북미, 유럽, 아시아태평양에서 AI 도입이 가속화되고 있으며, 미국이 투자, 파트너십, AI 스타트업 활동에서 선두를 달리고 있습니다. 화이자, 노바티스, 로슈, 아스트라제네카, 사노피 등 세계 제약사들은 AI를 우선시하는 생명공학 기업 및 학계와 적극적으로 제휴하여 독자적인 알고리즘과 차세대 신약개발 엔진을 공동 개발하고 있습니다. 구글(딥마인드), IBM 왓슨헬스, 엔비디아와 같은 대형 하이테크 기업도 제약사와 제휴하여 생물의학 연구에 맞는 컴퓨팅 인프라와 AI 플랫폼을 제공합니다.
유럽은 특히 영국, 독일, 스위스에서 강력한 생명공학 생태계와 정부 자금 지원을 통해 부문 간 협업을 촉진하는 등 AI를 활용한 제약 혁신의 중심지로 부상하고 있습니다. 중국과 한국이 주도하는 아시아태평양은 국가 AI 전략, 인구 규모의 건강 데이터세트, 빠르게 발전하는 임상시험 역량으로 인해 강력한 성장세를 보이고 있으며, BenevolentAI, Insilico Medicine, Recursion, Atomwise 등 신약개발 AI 전문 스타트업이 등장하고 있습니다. CRO(임상시험 수탁기관)와 CDMO(의약품개발수탁기관)도 AI를 통합하여 임상 및 상업화 단계의 서비스 제공을 강화하고 있습니다. 서비스 제공을 강화하고 있습니다.
제약 분야 AI의 세계 성장 원동력은?
제약 분야 AI 시장의 성장은 의약품 개발 비용과 복잡성 증가, 생물의학 데이터의 폭발적인 증가, 정밀의료로의 전환 등 여러 가지 복합적인 요인에 의해 주도되고 있습니다. 주요 촉진요인은 유전체, 단백질체학, 이미지, EHR, 시장 인텔리전스에 걸친 다차원 데이터세트를 통합하고 분석하여 증거에 기반한 신속한 의사결정을 지원하는 AI 시스템의 능력이 향상되고 있다는 점입니다. 규제 당국도 AI를 활용한 혁신에 대해 관대한 태도를 보이고 있으며, FDA와 EMA는 실제 데이터 활용, 알고리즘의 투명성, 디지털 바이오마커 검증에 대한 가이드라인을 제공합니다.
벤처캐피털 투자, M&A 활동, 제약사와 AI 공급업체 간의 전략적 제휴는 혁신 파이프라인을 가속화하고 있으며, COVID-19 팬데믹은 치료 모델링, 백신 개발, 역학 추적에 있으며, AI의 역할을 더욱 입증하고 AI의 확장성과 영향력에 대한 조직의 신뢰를 강화했습니다. AI의 확장성과 영향력에 대한 조직의 신뢰를 강화했습니다. 클라우드 컴퓨팅, 데이터 상호운용성 향상, 협업 학습 모델은 전 세계 데이터 사일로를 가로지르는 안전한 대규모 모델 학습을 가능하게 함으로써 AI 도입에 대한 장벽을 낮추고 있습니다. 중요한 전략적 질문이 떠오르고 있습니다. 제약업계가 AI를 충분히 활용하여 개발 기간을 단축하고, 실패율을 낮추며, 보다 안전하고 효과적인 치료법을 환자에게 더 빨리 제공할 수 있는가?
부문
제공(하드웨어, 소프트웨어, 서비스), 테크놀러지(자연언어처리, 상황 인식 처리, 딥러닝, 쿼리 방법, 기타 테크놀러지), 약제 유형(대형 분자, 소형 분자), 애플리케이션(Drug Discovery, 임상시험, 연구개발, 의약품 제조·공급망, 기타 애플리케이션), 최종사용자(제약·바이오테크놀러지 기업, 병원·진단 센터, 학술·연구기관, 기타 최종사용자)
조사 대상 기업의 예(주목 41사)
Absci Corporation
Anima Biotech
Antiverse
Atomwise
BenevolentAI
BPGbio
Cloud Pharmaceuticals
Deep Genomics
Exscientia
Generate Biomedicines
GNS Healthcare
Healx
IBM Watson Health
Iktos
Insilico Medicine
Insitro
InveniAI
Isomorphic Labs
Microsoft Corporation
Model Medicines
관세 영향 계수
Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 인위적인 수입원가 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.
Global Industry Analysts는 세계 주요 수석 이코노미스트(1,4,949명), 싱크탱크(62개 기관), 무역 및 산업 단체(171개 기관)의 전문가들의 의견을 면밀히 검토하여 생태계에 미치는 영향을 평가하고 새로운 시장 현실에 대응하고 있습니다. 모든 주요 국가의 전문가와 경제학자들이 관세와 그것이 자국에 미치는 영향에 대한 의견을 추적 조사했습니다.
Global Industry Analysts는 이러한 혼란이 향후 2-3개월 내에 마무리되고 새로운 세계 질서가 보다 명확하게 확립될 것으로 예상하고 있으며, Global Industry Analysts는 이러한 상황을 실시간으로 추적하고 있습니다.
2025년 4월: 협상 단계
이번 4월 보고서에서는 관세가 세계 시장 전체에 미치는 영향과 지역별 시장 조정에 대해 소개합니다. 당사의 예측은 과거 데이터와 진화하는 시장 영향요인을 기반으로 합니다.
2025년 7월: 최종 관세 재설정
고객님들께는 각 국가별 최종 리셋이 발표된 후 7월에 무료 업데이트 버전을 제공해 드립니다. 최종 업데이트 버전에는 명확하게 정의된 관세 영향 분석이 포함되어 있습니다.
상호 및 양자 간 무역과 관세의 영향 분석 :
미국 <>중국 <>멕시코 <>캐나다 <>EU <>일본 <>인도 <>기타 176개국
업계 최고의 이코노미스트: Global Industry Analysts의 지식 기반은 국가, 싱크탱크, 무역 및 산업 단체, 대기업, 그리고 세계 계량 경제 상황의 전례 없는 패러다임 전환의 영향을 공유하는 분야별 전문가 등 가장 영향력 있는 수석 이코노미스트 그룹을 포함한 14,949명의 이코노미스트를 추적하고 있습니다. 16,491개 이상의 보고서 대부분에 마일스톤에 기반한 2단계 출시 일정이 적용되어 있습니다.
목차
제1장 조사 방법
제2장 개요
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
기타 유럽
아시아태평양
기타 지역
제4장 경쟁
KSA
영문 목차
영문목차
Global Artificial Intelligence in Pharmaceutical Market to Reach US$5.8 Billion by 2030
The global market for Artificial Intelligence in Pharmaceutical estimated at US$1.2 Billion in the year 2024, is expected to reach US$5.8 Billion by 2030, growing at a CAGR of 30.1% over the analysis period 2024-2030. AI Hardware, one of the segments analyzed in the report, is expected to record a 31.6% CAGR and reach US$3.6 Billion by the end of the analysis period. Growth in the AI Software segment is estimated at 27.0% CAGR over the analysis period.
The U.S. Market is Estimated at US$314.5 Million While China is Forecast to Grow at 28.5% CAGR
The Artificial Intelligence in Pharmaceutical market in the U.S. is estimated at US$314.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$873.7 Million by the year 2030 trailing a CAGR of 28.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 27.7% and 25.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 20.8% CAGR.
Global Artificial Intelligence in Pharmaceutical Market - Key Trends & Drivers Summarized
Why Is Artificial Intelligence Becoming a Game-Changer in the Pharmaceutical Industry?
Artificial Intelligence (AI) is rapidly transforming the pharmaceutical industry by reshaping how drugs are discovered, developed, manufactured, and brought to market. As drug development becomes increasingly costly, time-intensive, and data-heavy, AI offers powerful tools to streamline R&D workflows, identify novel drug candidates, and optimize clinical trial design. Traditional pharma models often take over a decade and billions of dollars to bring a single drug to market, with high attrition rates. AI, particularly machine learning (ML) and deep learning, is addressing these inefficiencies by accelerating hit-to-lead identification, predicting compound efficacy and toxicity, and repurposing existing drugs with greater precision and speed.
AI's ability to analyze vast datasets-ranging from omics data and electronic health records to biomedical literature and molecular libraries-enables a more targeted and hypothesis-driven approach to drug discovery. Pharma companies are leveraging AI to uncover hidden relationships between disease mechanisms and therapeutic pathways, drastically reducing the trial-and-error component of early-stage R&D. Additionally, AI is being deployed in commercial operations to personalize physician outreach, optimize pricing strategies, forecast demand, and improve patient adherence. As pharma transitions toward data-centric innovation models, AI is becoming central to competitive advantage and operational agility.
How Are AI-Driven Platforms Accelerating Drug Discovery and Clinical Development?
AI is significantly compressing timelines in drug discovery through predictive modeling, molecular simulations, and automated high-throughput screening. Deep learning algorithms trained on vast compound datasets can predict biological activity, binding affinity, ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties, and off-target effects, allowing researchers to focus on the most promising candidates. Generative AI models are designing entirely new molecular structures with desired properties, while natural language processing (NLP) tools extract actionable insights from scientific literature and clinical trial databases, enriching target validation and hypothesis generation.
In clinical development, AI is transforming trial design and execution. Machine learning models are being used to identify optimal trial sites, predict patient recruitment rates, and select populations most likely to respond to therapy based on genetic or phenotypic data. AI-enabled remote monitoring and real-world data integration are enhancing adaptive trial designs and post-market surveillance, improving both safety assessments and regulatory compliance. These efficiencies not only reduce cost and attrition but also open the door to precision trials that align with personalized medicine paradigms. As AI continues to bridge the gap between discovery and delivery, it is reshaping the pharmaceutical development lifecycle into a faster, more predictive, and patient-centric process.
Where Is Adoption of AI in Pharmaceuticals Accelerating and Which Stakeholders Are Leading the Charge?
AI adoption in the pharmaceutical industry is accelerating across North America, Europe, and Asia-Pacific, with the U.S. leading in terms of investment, partnerships, and AI start-up activity. Global pharma leaders such as Pfizer, Novartis, Roche, AstraZeneca, and Sanofi are actively partnering with AI-first biotech firms and academic institutions to co-develop proprietary algorithms and next-gen drug discovery engines. Major tech players like Google (DeepMind), IBM Watson Health, and NVIDIA are also collaborating with pharma to provide computing infrastructure and AI platforms tailored for biomedical research.
Europe is emerging as a hub for AI-powered pharmaceutical innovation, particularly in the U.K., Germany, and Switzerland, where strong biotech ecosystems and government funding are fueling cross-sector collaboration. Asia-Pacific, led by China and South Korea, is seeing robust growth driven by national AI strategies, population-scale health datasets, and rapidly advancing clinical trial capabilities. Startups specializing in AI for drug discovery, such as BenevolentAI, Insilico Medicine, Recursion, and Atomwise, are gaining traction by offering scalable platforms that integrate cheminformatics, bioinformatics, and predictive analytics. CROs (Contract Research Organizations) and CDMOs (Contract Development and Manufacturing Organizations) are also integrating AI to enhance service offerings across clinical and commercial stages.
What Is Driving the Global Growth of AI in the Pharmaceutical Sector?
The growth in the artificial intelligence in pharmaceutical market is driven by several converging factors, including the escalating cost and complexity of drug development, the explosion of biomedical data, and the shift toward precision medicine. A primary driver is the increasing ability of AI systems to integrate and analyze multidimensional datasets-spanning genomics, proteomics, imaging, EHRs, and market intelligence-to support faster, evidence-based decisions. Regulatory agencies are also showing openness to AI-enabled innovations, with the FDA and EMA providing guidance on real-world data use, algorithm transparency, and digital biomarker validation.
Venture capital investment, M&A activity, and strategic alliances between pharma and AI vendors are accelerating innovation pipelines. The COVID-19 pandemic further validated AI’s role in therapeutic modeling, vaccine development, and epidemiological tracking, reinforcing institutional confidence in AI's scalability and impact. Cloud computing, improved data interoperability, and federated learning models are also reducing the barriers to AI adoption by enabling secure, large-scale model training across global data silos. As AI becomes embedded in end-to-end pharmaceutical operations, a critical strategic question emerges: Can the pharmaceutical industry fully harness AI to shorten development timelines, reduce failure rates, and bring safer, more effective therapies to patients faster than ever before?
SCOPE OF STUDY:
The report analyzes the Artificial Intelligence in Pharmaceutical market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Offering (Hardware, Software, Services); Technology (Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method, Other Technologies); Drug Type (Large Molecules, Small Molecules); Application (Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain, Other Applications); End-User (Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes, Other End-Users)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
Select Competitors (Total 41 Featured) -
Absci Corporation
Anima Biotech
Antiverse
Atomwise
BenevolentAI
BPGbio
Cloud Pharmaceuticals
Deep Genomics
Exscientia
Generate Biomedicines
GNS Healthcare
Healx
IBM Watson Health
Iktos
Insilico Medicine
Insitro
InveniAI
Isomorphic Labs
Microsoft Corporation
Model Medicines
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.
We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.
As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.
To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!
APRIL 2025: NEGOTIATION PHASE
Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.
JULY 2025 FINAL TARIFF RESET
Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.
Reciprocal and Bilateral Trade & Tariff Impact Analyses:
USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.
Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.
COMPLIMENTARY PREVIEW
Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Artificial Intelligence in Pharmaceutical - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
AI-Driven Drug Discovery Reduces Preclinical Development Timelines Across Therapeutic Areas
Machine Learning Enhances Candidate Molecule Screening and Predictive Toxicology in Pharma
Clinical Trial Design Optimization Through AI Improves Patient Stratification and Endpoint Selection
Integration of AI in Drug Repurposing Unlocks New Revenue Paths for Established Pharma Pipelines
Virtual Screening and De Novo Drug Design Tools Accelerate Innovation in Pharma R&D
AI-Enhanced Pharmacovigilance Improves Real-Time Detection of Adverse Drug Reactions
Regulatory Engagement With AI-Supported Submissions Encourages Broader Pharmaceutical Adoption
Natural Language Processing Automates Literature Review and IP Landscape Analysis for Drug Development
AI Integration in Manufacturing Quality Control Improves Yield and Reduces Batch Failures
Oncology and Rare Disease Drug Pipelines See Early Wins Through AI-Augmented Discovery
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Artificial Intelligence in Pharmaceutical Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 3: World 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
TABLE 4: World Recent Past, Current & Future Analysis for Hardware by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 5: World 6-Year Perspective for Hardware by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 6: World Recent Past, Current & Future Analysis for Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 7: World 6-Year Perspective for Software by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 9: World 6-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 10: World Recent Past, Current & Future Analysis for Small Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 11: World 6-Year Perspective for Small Molecules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 12: World Recent Past, Current & Future Analysis for Large Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 13: World 6-Year Perspective for Large Molecules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 15: World 6-Year Perspective for Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 16: World Recent Past, Current & Future Analysis for Clinical Trial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 17: World 6-Year Perspective for Clinical Trial by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 18: World Recent Past, Current & Future Analysis for Research & Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 19: World 6-Year Perspective for Research & Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Drug Manufacturing & Supply Chain by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 21: World 6-Year Perspective for Drug Manufacturing & Supply Chain by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 22: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 23: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 24: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 25: World 6-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Hospitals & Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 27: World 6-Year Perspective for Hospitals & Diagnostic Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 28: World Recent Past, Current & Future Analysis for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 29: World 6-Year Perspective for Academic & Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 30: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 31: World 6-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 32: World Recent Past, Current & Future Analysis for Natural Language Processing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 33: World 6-Year Perspective for Natural Language Processing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 34: World Recent Past, Current & Future Analysis for Context-aware Processing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 35: World 6-Year Perspective for Context-aware Processing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 36: World Recent Past, Current & Future Analysis for Deep Learning by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 37: World 6-Year Perspective for Deep Learning by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 38: World Recent Past, Current & Future Analysis for Querying Method by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 39: World 6-Year Perspective for Querying Method by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 40: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 41: World 6-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Artificial Intelligence in Pharmaceutical Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 42: USA Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Offering - Hardware, Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 43: USA 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Offering - Percentage Breakdown of Value Sales for Hardware, Software and Services for the Years 2025 & 2030
TABLE 44: USA Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 45: USA 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2025 & 2030
TABLE 46: USA Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Application - Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 47: USA 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Application - Percentage Breakdown of Value Sales for Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications for the Years 2025 & 2030
TABLE 48: USA Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by End-user - Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 49: USA 6-Year Perspective for Artificial Intelligence in Pharmaceutical by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users for the Years 2025 & 2030
TABLE 50: USA Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Technology - Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 51: USA 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Technology - Percentage Breakdown of Value Sales for Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies for the Years 2025 & 2030
CANADA
TABLE 52: Canada Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Offering - Hardware, Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 53: Canada 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Offering - Percentage Breakdown of Value Sales for Hardware, Software and Services for the Years 2025 & 2030
TABLE 54: Canada Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 55: Canada 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2025 & 2030
TABLE 56: Canada Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Application - Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 57: Canada 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Application - Percentage Breakdown of Value Sales for Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications for the Years 2025 & 2030
TABLE 58: Canada Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by End-user - Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 59: Canada 6-Year Perspective for Artificial Intelligence in Pharmaceutical by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users for the Years 2025 & 2030
TABLE 60: Canada Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Technology - Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 61: Canada 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Technology - Percentage Breakdown of Value Sales for Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies for the Years 2025 & 2030
JAPAN
Artificial Intelligence in Pharmaceutical Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 62: Japan Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Offering - Hardware, Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 63: Japan 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Offering - Percentage Breakdown of Value Sales for Hardware, Software and Services for the Years 2025 & 2030
TABLE 64: Japan Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 65: Japan 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2025 & 2030
TABLE 66: Japan Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Application - Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 67: Japan 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Application - Percentage Breakdown of Value Sales for Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications for the Years 2025 & 2030
TABLE 68: Japan Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by End-user - Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 69: Japan 6-Year Perspective for Artificial Intelligence in Pharmaceutical by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users for the Years 2025 & 2030
TABLE 70: Japan Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Technology - Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 71: Japan 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Technology - Percentage Breakdown of Value Sales for Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies for the Years 2025 & 2030
CHINA
Artificial Intelligence in Pharmaceutical Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 72: China Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Offering - Hardware, Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 73: China 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Offering - Percentage Breakdown of Value Sales for Hardware, Software and Services for the Years 2025 & 2030
TABLE 74: China Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 75: China 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2025 & 2030
TABLE 76: China Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Application - Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 77: China 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Application - Percentage Breakdown of Value Sales for Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications for the Years 2025 & 2030
TABLE 78: China Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by End-user - Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 79: China 6-Year Perspective for Artificial Intelligence in Pharmaceutical by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users for the Years 2025 & 2030
TABLE 80: China Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Technology - Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 81: China 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Technology - Percentage Breakdown of Value Sales for Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies for the Years 2025 & 2030
EUROPE
Artificial Intelligence in Pharmaceutical Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 82: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 83: Europe 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
TABLE 84: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Offering - Hardware, Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 85: Europe 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Offering - Percentage Breakdown of Value Sales for Hardware, Software and Services for the Years 2025 & 2030
TABLE 86: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 87: Europe 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2025 & 2030
TABLE 88: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Application - Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 89: Europe 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Application - Percentage Breakdown of Value Sales for Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications for the Years 2025 & 2030
TABLE 90: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by End-user - Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 91: Europe 6-Year Perspective for Artificial Intelligence in Pharmaceutical by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users for the Years 2025 & 2030
TABLE 92: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Technology - Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 93: Europe 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Technology - Percentage Breakdown of Value Sales for Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies for the Years 2025 & 2030
FRANCE
Artificial Intelligence in Pharmaceutical Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 94: France Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Offering - Hardware, Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 95: France 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Offering - Percentage Breakdown of Value Sales for Hardware, Software and Services for the Years 2025 & 2030
TABLE 96: France Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 97: France 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2025 & 2030
TABLE 98: France Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Application - Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 99: France 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Application - Percentage Breakdown of Value Sales for Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications for the Years 2025 & 2030
TABLE 100: France Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by End-user - Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 101: France 6-Year Perspective for Artificial Intelligence in Pharmaceutical by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users for the Years 2025 & 2030
TABLE 102: France Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Technology - Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 103: France 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Technology - Percentage Breakdown of Value Sales for Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies for the Years 2025 & 2030
GERMANY
Artificial Intelligence in Pharmaceutical Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 104: Germany Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Offering - Hardware, Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 105: Germany 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Offering - Percentage Breakdown of Value Sales for Hardware, Software and Services for the Years 2025 & 2030
TABLE 106: Germany Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 107: Germany 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2025 & 2030
TABLE 108: Germany Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Application - Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 109: Germany 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Application - Percentage Breakdown of Value Sales for Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications for the Years 2025 & 2030
TABLE 110: Germany Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by End-user - Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 111: Germany 6-Year Perspective for Artificial Intelligence in Pharmaceutical by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users for the Years 2025 & 2030
TABLE 112: Germany Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Technology - Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 113: Germany 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Technology - Percentage Breakdown of Value Sales for Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies for the Years 2025 & 2030
ITALY
TABLE 114: Italy Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Offering - Hardware, Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 115: Italy 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Offering - Percentage Breakdown of Value Sales for Hardware, Software and Services for the Years 2025 & 2030
TABLE 116: Italy Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 117: Italy 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2025 & 2030
TABLE 118: Italy Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Application - Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 119: Italy 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Application - Percentage Breakdown of Value Sales for Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications for the Years 2025 & 2030
TABLE 120: Italy Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by End-user - Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 121: Italy 6-Year Perspective for Artificial Intelligence in Pharmaceutical by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users for the Years 2025 & 2030
TABLE 122: Italy Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Technology - Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 123: Italy 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Technology - Percentage Breakdown of Value Sales for Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies for the Years 2025 & 2030
UNITED KINGDOM
Artificial Intelligence in Pharmaceutical Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 124: UK Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Offering - Hardware, Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 125: UK 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Offering - Percentage Breakdown of Value Sales for Hardware, Software and Services for the Years 2025 & 2030
TABLE 126: UK Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 127: UK 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2025 & 2030
TABLE 128: UK Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Application - Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 129: UK 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Application - Percentage Breakdown of Value Sales for Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications for the Years 2025 & 2030
TABLE 130: UK Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by End-user - Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 131: UK 6-Year Perspective for Artificial Intelligence in Pharmaceutical by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users for the Years 2025 & 2030
TABLE 132: UK Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Technology - Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 133: UK 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Technology - Percentage Breakdown of Value Sales for Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies for the Years 2025 & 2030
REST OF EUROPE
TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Offering - Hardware, Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 135: Rest of Europe 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Offering - Percentage Breakdown of Value Sales for Hardware, Software and Services for the Years 2025 & 2030
TABLE 136: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 137: Rest of Europe 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2025 & 2030
TABLE 138: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Application - Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 139: Rest of Europe 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Application - Percentage Breakdown of Value Sales for Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications for the Years 2025 & 2030
TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by End-user - Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 141: Rest of Europe 6-Year Perspective for Artificial Intelligence in Pharmaceutical by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users for the Years 2025 & 2030
TABLE 142: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Technology - Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 143: Rest of Europe 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Technology - Percentage Breakdown of Value Sales for Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies for the Years 2025 & 2030
ASIA-PACIFIC
Artificial Intelligence in Pharmaceutical Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 144: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Offering - Hardware, Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 145: Asia-Pacific 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Offering - Percentage Breakdown of Value Sales for Hardware, Software and Services for the Years 2025 & 2030
TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 147: Asia-Pacific 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2025 & 2030
TABLE 148: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Application - Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 149: Asia-Pacific 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Application - Percentage Breakdown of Value Sales for Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications for the Years 2025 & 2030
TABLE 150: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by End-user - Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 151: Asia-Pacific 6-Year Perspective for Artificial Intelligence in Pharmaceutical by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users for the Years 2025 & 2030
TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Technology - Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 153: Asia-Pacific 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Technology - Percentage Breakdown of Value Sales for Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies for the Years 2025 & 2030
REST OF WORLD
TABLE 154: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Offering - Hardware, Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 155: Rest of World 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Offering - Percentage Breakdown of Value Sales for Hardware, Software and Services for the Years 2025 & 2030
TABLE 156: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 157: Rest of World 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2025 & 2030
TABLE 158: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Application - Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 159: Rest of World 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Application - Percentage Breakdown of Value Sales for Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications for the Years 2025 & 2030
TABLE 160: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by End-user - Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 161: Rest of World 6-Year Perspective for Artificial Intelligence in Pharmaceutical by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users for the Years 2025 & 2030
TABLE 162: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Technology - Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 163: Rest of World 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Technology - Percentage Breakdown of Value Sales for Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies for the Years 2025 & 2030
